Loading provider…
Loading provider…
Hematology & Oncology Physician in Fresno, CA
NPI: 1326087917Primary Employer
Ccare
ccare.com
HQ Phone
Get D.O. Steven's Phone Numberphone_androidMobile
Get D.O. Steven's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State License
2002 - 2025
VA State License
1999 - 2016
FL State License
1991 - 2004
NC State License
2001 - 2004
MI State License
1984 - 1985

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
Naval Medical Center (San Diego)
Fellowship • Hematology and Medical Oncology
1993 - 1996
National Capital Consortium
Residency • Internal Medicine
1988 - 1991
New York Institute of Technology College of Osteopathic Medicine - Old Westbury
nyit.edu
Medical School
Until 1984
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 36415Insertion of needle into vein for collection of blood sample | 625 | 2,217 |
| 2 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 604 | 2,337 |
| 3 | 80053Blood test, comprehensive group of blood chemicals | 486 | 1,336 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 463 | 721 |
| 5 | 99214Established patient office or other outpatient visit, 30-39 minutes | 374 | 1,120 |
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12...
Authors: Dan-Yun Ruan, Hao-Xiang Wu, Ye Xu, Pamela N Munster, Yanhong Deng
Authors: Messeha, Samia S, Nezami, Mohammad A, Hager, Steven, Soliman, Karam F A
Journal: Anticancer Res
A Rare Presentation of a Non-Asian Female With Metastatic Non-small-cell Lung Cancer HarboringL747P Mutation With Clinical Response to Multi-targeted Epigenetic andInh...
Authors: Samia S Messeha, Mohammad A Nezami, Steven Hager, Karam F A Soliman
Lead Sponsor: Vaccinex Inc.
Collaborators: Merck Sharp & Dohme LLC
Intervention / Treatment: DRUG: pepinemab + pembrolizumab
Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Collaborators: Merck Sharp & Dohme LLC
Intervention / Treatment: DRUG: pembrolizumab, DRUG: brentuximab vedotin
Lead Sponsor: ImmunoGen, Inc.
Intervention / Treatment: DRUG: Mirvetuximab Soravtansine